arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2013-19-3-204-211arthyper-137Research ArticleОБЗОРREVIEWДОСТИЖЕНИЕ ЦЕЛЕВЫХ ДОЗ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ ИЛИ ЦЕЛЕВЫХ ПОКАЗАТЕЛЕЙ: ЧТО ДОЛЖНО СЧИТАТЬСЯ ГЛАВНЫМ УСЛОВИЕМ ОПТИМАЛЬНОГО СНИЖЕНИЯ РИСКА РАЗВИТИЯ ОСЛОЖНЕНИЙ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ?TARGET DOSES OR TARGET PARAMETERS: WHAT IS PIVOTAL FOR CARDIOVASCULAR RISK DECREASE?ГиляревскийС. Р.GilyarevskiyS. R.

Доктор  медицинских наук, профессор кафедры клинической фармакологии и терапии РМАПО.

Контактная информация: ГБОУ ДПО ≪Российская медицинская академия последипломного образования≫, ул. Баррикадная, д. 2/1, Москва, Россия, 123995 (Гиляревский Сергей Руджерович).

 

Corresponding author: Russian Medical Academy of Advanced Studies, 2/1 Barrikadnaya st., Moscow, Russia, 123995 (Sergey R. Gilyarevskiy, MD, PhD, Professor at the Department of Clinical Pharmacology and Therapy at Russian Medical Academy of Advanced Studies).

Кузьмина.. М.KuzminaI. M.

Ведущий научный сотрудник кардиологического отделения для больных инфарктом миокарда Научно-исследовательского института скорой помощи им. Н.В. Склифосовского

ГолшмидМ. В.GolshmidM. V.

Доцент кафедры клинической фармакологии и терапии РМАПО

СиницинаИ. И.SinitsinaI. I.

Профессор кафедры клинической фармакологии и терапии РМАПО

ЗахароваГ. Ю.ZakharovaG. U.

Доцент кафедры клинической фармакологии и терапии РМАПО

Russian Medical Academy of Advanced Studies, Moscow

Российская медицинская академия последипломного образования, МоскваРоссияRussian Medical Academy of Advanced Studies, MoscowRussian FederationНаучно-исследовательский институт скорой помощи им. Н. В. СклифосовскогоРоссияResearch Institute of the Emergency Care named after N.V. Sklifosofskiy, MoscowRussian Federation201328062013193204211Copyright © Гиляревский С.Р., Кузьмина ..М., Голшмид М.В., Синицина И.И., Захарова Г.Ю., 20132013Гиляревский С.Р., Кузьмина ..М., Голшмид М.В., Синицина И.И., Захарова Г.Ю.Gilyarevskiy S.R., Kuzmina I.M., Golshmid M.V., Sinitsina I.I., Zakharova G.U.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/137

В статье обсуждаются современные подходы к подбору эффективной терапии, применяемой для вторичной профилактики развития тяжелых осложнений сердечно-сосудистых заболеваний. Рассматриваются клинические ситуации, когда использование целевых доз препаратов или целевых уровней определенных показателей становится необходимым условием эффективности применяемой терапии. Обсуждается важность соблюдения доказательных подходов при подборе доз ингибиторов ангиотензинпревращающегофермента, статинов и β-блокаторов ия, 123995 (Гиляревский Сергей Руджерович).

 

 

 

 

The article reviews the up-to-date approaches to the secondary prevention of cardiovascular complications, and the clinical situations when the target drug doses or target parameter levels are important to achieve an effect. We discuss the role of available evidence in titrating doses of angiotensin-converting enzyme inhibitors, statins and beta-blockers.

целевые дозыингибиторы ангиотензинпревращающего ферментастатиныосложнения сердечно-сосудистых заболеванийβ-блокаторыReferencesSchwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial // J. Am. Med. Assoc. — 2001. — Vol. 285, № 13. — P. 1711–1718.Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial // J. Am. Med. Assoc. — 2001. — Vol. 285, № 13. — P. 1711–1718.Nainggolan L. Is MIRACL a miracle or not? — [Electronic resource]. — Available at: www.theheart.org/article/196489.do. Fri, 17 Nov 2000.Nainggolan L. Is MIRACL a miracle or not? — [Electronic resource]. — Available at: www.theheart.org/article/196489.do. Fri, 17 Nov 2000.McAlister F.A., Wiebe N., Ezekowitz J.A. et al. Metaanalysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure // Ann. Intern. Med. — 2009. — Vol. 150, № 11. — P. 784–794McAlister F.A., Wiebe N., Ezekowitz J.A. et al. Metaanalysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure // Ann. Intern. Med. — 2009. — Vol. 150, № 11. — P. 784–794Swedberg K., Komajda M., Bohm M. et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an infl uence of beta-blocker dose? Findings From the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Study // J. Am. Coll. Cardiol. — 2012. — Vol. 59, № 22. — P. 1938–1945.Swedberg K., Komajda M., Bohm M. et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an infl uence of beta-blocker dose? Findings From the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Study // J. Am. Coll. Cardiol. — 2012. — Vol. 59, № 22. — P. 1938–1945.Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients // N. Engl. J. Med. — 2000. — Vol. 342. — P. 145–153. [Erratа, N. Engl. J. Med. — 2000. — Vol. 342, № 10. — P. 784; Vol. 342, № 18. — Р. 1376.]Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients // N. Engl. J. Med. — 2000. — Vol. 342. — P. 145–153. [Erratа, N. Engl. J. Med. — 2000. — Vol. 342, № 10. — P. 784; Vol. 342, № 18. — Р. 1376.]Fox K.M., EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Effi cacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. — 2003. — Vol. 362, № 9386. — P. 782–788.Fox K.M., EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Effi cacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. — 2003. — Vol. 362, № 9386. — P. 782–788.Nissen S.E., Tuzcu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure // J. Am. Med. Assoc. — 2004. — Vol. 292, № 18. — P. 2217–2226.Nissen S.E., Tuzcu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure // J. Am. Med. Assoc. — 2004. — Vol. 292, № 18. — P. 2217–2226.Braunwald E., Domanski M.J., Fowler S.E. et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease // N. Engl. J. Med. — 2004. — Vol. 351, № 20. — P. 2058–2068.Braunwald E., Domanski M.J., Fowler S.E. et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease // N. Engl. J. Med. — 2004. — Vol. 351, № 20. — P. 2058–2068.Marre M., Lievre M., Chatellier G. et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) // Br. Med. J. — 2004. — Vol. 328, № 7438. — P. 495–500.Marre M., Lievre M., Chatellier G. et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) // Br. Med. J. — 2004. — Vol. 328, № 7438. — P. 495–500.Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Effi cacy (AIRE) Study Investigators // Lancet. — 1993. — Vol. 342, № 8875. — P. 821–828.Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Effi cacy (AIRE) Study Investigators // Lancet. — 1993. — Vol. 342, № 8875. — P. 821–828.van Vark L.C., Bertrand M., Akkerhuis K.M. et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients // Eur. Heart J. — 2012. — Vol. 33, № 16. — P. 2088–2097.van Vark L.C., Bertrand M., Akkerhuis K.M. et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients // Eur. Heart J. — 2012. — Vol. 33, № 16. — P. 2088–2097.Yan X.W., Investigators for the study on the tolerability of perindopril. The study on the tolerability of perindopril in patients with stable coronary heart disease // Zhonghua Xin Xue Guan Bing Za Zhi. — 2007. — Vol. 35, № 12. — P. 11301132.Yan X.W., Investigators for the study on the tolerability of perindopril. The study on the tolerability of perindopril in patients with stable coronary heart disease // Zhonghua Xin Xue Guan Bing Za Zhi. — 2007. — Vol. 35, № 12. — P. 11301132.Butt D.A., Mamdani M., Austin P.C., Tu K., Gomes T., Glazier R.H. The risk of hip fracture after initiating antihypertensive drugs in the elderly // Arch. Intern. Med. — 2012. — Vol. 172, № 22. — P. 1739–1744.Butt D.A., Mamdani M., Austin P.C., Tu K., Gomes T., Glazier R.H. The risk of hip fracture after initiating antihypertensive drugs in the elderly // Arch. Intern. Med. — 2012. — Vol. 172, № 22. — P. 1739–1744.Beckett N.S., Peters R., Fletcher A.E. et al. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358, № 18. — P. 1887–1898.Beckett N.S., Peters R., Fletcher A.E. et al. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358, № 18. — P. 1887–1898.Ogilvie R.I., Anand S., Roy P., De Souza S. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study // Clin. Drug Investig. — 2008. — Vol. 28, № 11. — P. 673–686.Ogilvie R.I., Anand S., Roy P., De Souza S. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study // Clin. Drug Investig. — 2008. — Vol. 28, № 11. — P. 673–686.Savarese G., Costanzo P., Cleland J.G. et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure // J. Am. Coll. Cardiol. — 2013. — Vol. 61, № 2. — P. 131–142.Savarese G., Costanzo P., Cleland J.G. et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure // J. Am. Coll. Cardiol. — 2013. — Vol. 61, № 2. — P. 131–142.Moher D., Liberati A., Tetzlaff J., Altman D.G.; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement // J. Clin. Epidemiol. — 2009. — Vol. 62, № 10. — P. 1006–1012.Moher D., Liberati A., Tetzlaff J., Altman D.G.; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement // J. Clin. Epidemiol. — 2009. — Vol. 62, № 10. — P. 1006–1012.

The authors declare that there are no conflicts of interest present.